Finance

Lists
PYXS:NASDAQ
Pyxis Oncology Inc
4,00 US$
+2,96%
(+0,12) 1D
8 სექ, 10:18:55 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PYXS...
Open
4,00 US$
High
4,15 US$
Low
3,90 US$
Mkt. cap
334,47 მლნ.
Avg. vol.
1,27 მლნ.
Volume
360,79 ათ.
52-wk high
5,55 US$
52-wk low
1,03 US$
EPS
-1,40 US$
Beta
1,34
Shares outstanding
83,41 მლნ.
No. of employees
56
Open
4,00 US$
High
4,15 US$
Low
3,90 US$
Mkt. cap
334,47 მლნ.
Avg. vol.
1,27 მლნ.
Volume
360,79 ათ.
52-wk high
5,55 US$
52-wk low
1,03 US$
EPS
-1,40 US$
Beta
1,34
Shares outstanding
83,41 მლნ.
No. of employees
56
News stories
From web sources and news partners
TipRanks
TipRanks
·
2 საათის წინ
Pyxis Oncology Elevates Thomas Civik to Permanent CEO
Investing.com
Investing.com
·
2 საათის წინ
Pyxis Oncology names Thomas Civik as permanent CEO and chairman
Stock Titan
Stock Titan
·
2 საათის წინ
Pyxis Oncology (PYXS) CEO receives 2.5M options at $3.89
Yahoo! Finance Canada
Yahoo! Finance Canada
·
2 საათის წინ
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
About Pyxis Oncology Inc
CEO-
Employees56
Founded2018
Headquartersბოსტონი, მასაჩუსეტსი, ამერიკის შეერთებული შტატები
Sector-
Websitepyxisoncology.com
Analyst ratings
Based on 8 analysts giving stock ratings to PYXS in the past 3 months
Strong buy
Buy
7
Hold
1
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for PYXS in the last 3 months.
Highest
Current 4,00 US$
12,00 US$ (+199,63%)
Average
7,14 US$ (+78,28%)
Lowest
5,00 US$ (+24,84%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
7,00 US$
+74,8%
08/18/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
7,00 US$
+74,8%
08/17/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
6,00 US$
+49,8%
08/14/2026
Leonid Timashev
RBC Capital
Buy
Maintained
5,00 US$
+24,8%
08/13/2026
Robert Driscoll
Wedbush
Buy
Reiterated
6,00 US$
+49,8%
08/14/2026
Derek Archila
Wells Fargo
Buy
Reiterated
12,00 US$
+199,6%
08/14/2026
Andy Hsieh
William Blair
Hold
Maintained
-
-
08/13/2026
Unknown Analyst
Guggenheim
Buy
Maintained
7,00 US$
+74,8%
06/29/2026
Last report
13 აგვ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,40 US$ / -0,35 US$
-14,29%miss
Revenue / Est. (USD)
- / 22,22 ათ.
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
11,04 მლნ.
-
-
Cost of goods sold
-
2,39 მლნ.
-
-
Cost of revenue
-
2,39 მლნ.
-
-
Research and development expenses
17,81 მლნ.
21,71 მლნ.
19,98 მლნ.
16,06 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,97 მლნ.
4,54 მლნ.
3,75 მლნ.
9,54 მლნ.
Operating expense
22,78 მლნ.
26,25 მლნ.
23,73 მლნ.
25,60 მლნ.
Total operating expenses
22,78 მლნ.
28,64 მლნ.
23,73 მლნ.
25,60 მლნ.
Operating income
-22,78 მლნ.
-17,60 მლნ.
-23,73 მლნ.
-25,60 მლნ.
Other non operating income
-
-
-
-
EBT including unusual items
-22,00 მლნ.
-17,00 მლნ.
-23,27 მლნ.
-25,35 მლნ.
EBT excluding unusual items
-22,00 მლნ.
-17,00 მლნ.
-23,27 მლნ.
-25,35 მლნ.
Income tax expense
-
1,10 მლნ.
-
-
Effective tax rate
-
-6,49%
-
-
Other operating expenses
-
-
-
-
Net income
-22,00 მლნ.
-18,11 მლნ.
-23,27 მლნ.
-25,35 მლნ.
Net profit margin
-
-164,03%
-
-
Earnings per share
-0,35
-0,29
-0,37
-0,40
Interest and investment income
774,00 ათ.
600,00 ათ.
457,00 ათ.
255,00 ათ.
Interest expense
-
-
-
-
Net interest expenses
774,00 ათ.
600,00 ათ.
457,00 ათ.
255,00 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-22,25 მლნ.
-14,71 მლნ.
-23,27 მლნ.
-25,30 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები